

Radiopharmaceuticals: Technologies and Global Markets

Market Research Report | 2025-04-10 | 163 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$4650.00
- 2-5 Users License \$5580.00
- Site License \$6696.00
- Enterprise License \$8035.00

Report description:

Description

Report Scope

This report analyzes the global market for radiopharmaceuticals, in terms of quantitative and qualitative data, to help readers understand the market, to assess business/growth strategies, and to make informed business decisions regarding radiopharmaceuticals. BCC Research estimates market data for 2023 (the base year) and 2024 and forecasts values for 2025 through 2029. The radiopharmaceuticals market segmentation is based on product, application, production method, countries and regions.

Drivers, restraints and opportunities in the radiopharmaceuticals market are also discussed. The report also describes the competitive landscape of the radiopharmaceuticals market and highlights emerging trends. The latest new products, acquisitions, and collaborations related to the radiopharmaceuticals market are also covered.

Report Includes

- 50 data tables and 68 additional tables
- Analyses of trends in the global market for radiopharmaceuticals, with revenue data for 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
- Estimates of the size, and revenue prospects for, the global market, along with a market share analysis by product type, application, production method, and region/country
- Facts and figures pertaining to the market dynamics, technological progress, regulations, prospects, innovations and the impact of various macroeconomic factors
- Insights derived from the Porter's Five Forces model, as well as global supply/value chain and PESTLE analyses
- An analysis of patents, clinical trials, emerging trends and other developments in the industry
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

venture funding outlook

- Profiles of leading companies, including Cardinal Health, Lantheus, Curium, GE Healthcare, and Novartis AG

Executive Summary

Summary:

The global radiopharmaceuticals market is expected to grow from \$10.3 billion in 2024 and is projected to reach \$21.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 16.4% during the forecast period of 2024 to 2029.

Radiopharmaceuticals are comprised of small amounts of radioisotopes that can be produced by irradiating a particular target inside a nuclear research reactor or particle accelerator, the latter of which uses cyclotrons. Once the radioisotopes are produced, they can be tagged to specific molecules depending on key biological characteristics through a linker that binds the radioisotope and the carrier together to produce radiopharmaceuticals.

Radiopharmaceuticals are used for diagnostic and therapeutic applications. Diagnostic radiopharmaceuticals travel to the targeted area based on the biological molecule's affinity. The radioactive isotope emits gamma rays or positrons, which are detected by molecular imaging devices such as single-photon emission computerized tomography (SPECT) and positron emission tomography (PET) scanners.

Therapeutic radiopharmaceuticals use high-energy cell-killing radioisotopes, such as actinium or lutetium. Therapeutic radiopharmaceuticals use radiation to destroy or weaken malfunctioning cells. The tagged compound delivers therapeutic doses of radiation to targeted body parts to regress or kill malignant cells. Radiopharmaceuticals are used primarily for treating prostate cancer, neuroendocrine tumors (NETs), and thyroid disorders.

Table of Contents:

Table of Contents

Chapter 1 Executive Summary

Market Outlook

Scope of Report

Market Summary

Chapter 2 Market Overview

Radiopharmaceuticals Overview

Preparation of Radiopharmaceuticals

Macroeconomic Factors Analysis

Porter's Five Forces Analysis

Threat of New Entrants (Moderate to Low)

Threat of Substitutes (Low to Moderate)

Bargaining Power of Suppliers (High)

Bargaining Power of Buyers (Moderate)

Industry Rivalry (Moderate)

Chapter 3 Market Dynamics

Market Drivers

Rising Prevalence of Cancer and Other Chronic Diseases

Unmet Need in Oncology

Precision Medicine

Nuclear Imaging Technologies

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Increasing Investment
Market Restraints
Manufacturing and Supply Chain Issues
Infrastructure and Specialized Imaging Equipment Requirements
Shortage of Skilled Professionals
Market Trends
Theranostics
Regional Diversification and Supply Chain Resilience
Opportunities
Radiopharmaceuticals Contract Manufacturing
PET Imaging in AD
Chapter 4 Regulatory Landscape
U.S.
European Union
Japan
Chapter 5 Emerging Technologies and Developments
Emerging Technologies
Ac-225 and Pb-212
Nanoparticle-based Theranostic Agents
Clinical Trials Analysis
Diagnostic Radiopharmaceuticals
Therapeutic Radiopharmaceuticals
Patent Analysis
Key Takeaways
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Radiopharmaceuticals Market, by Product Type
Diagnostic Radiopharmaceuticals
Diagnostic Radiopharmaceuticals Market, by Imaging Technique Type
Diagnostic Radiopharmaceuticals Market, by Production Method
Therapeutic Radiopharmaceuticals
Therapeutic Radiopharmaceuticals Market, by Product Type
Radiopharmaceuticals Market by Application
Market Overview
Oncology
Cardiology
Neurology
Others
Radiopharmaceuticals Market by Radioisotope Production Method
Market Overview
Market Revenue and Forecast
Geographic Breakdown
Radiopharmaceuticals Market Breakdown by Region
North America
Europe
Asia-Pacific
RoW

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Chapter 7 Competitive Intelligence
Overview
Diagnostic Radiopharmaceuticals
Therapeutic Radiopharmaceuticals
Chapter 8 Sustainability in Radiopharmaceuticals Market: ESG Perspective
Role of ESG in the Radiopharmaceuticals Industry
Environment
Social
Governance
ESG Risk Ratings
Conclusion
Chapter 9 Appendix
Methodology
Sources
Abbreviations
Company Profiles
BAYER AG
BLUE EARTH DIAGNOSTICS
BOSTON SCIENTIFIC CORP.
BWXT MEDICAL LTD.
CARDINAL HEALTH
CURIUM
ECKERT & ZIEGLER
GE HEALTHCARE
INTERNATIONAL ISOTOPES INC.
IONETIX CORP.
JUBILANT PHARMOVA LTD.
LANTHEUS
NMR
NOVARTIS AG
SIEMENS HEALTHINEERS AG
Emerging Start-ups/Market Disruptors

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Radiopharmaceuticals: Technologies and Global Markets

Market Research Report | 2025-04-10 | 163 pages | BCC Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4650.00
	2-5 Users License	\$5580.00
	Site License	\$6696.00
	Enterprise License	\$8035.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-08"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com